Joseph F. Merola

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

Philip J. Mease, Stephen Hall, Oliver FitzGerald et al. · New England Journal of Medicine · 2017 · 560 citations

Medicine, Pharmacology, Pharmacotherapy +14

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie et al. · Arthritis & Rheumatology · 2018 · 481 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Iain B. McInnes, J. Anderson, Marina Magrey et al. · New England Journal of Medicine · 2021 · 301 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

Richard Furie, Victoria P. Werth, Joseph F. Merola et al. · Journal of Clinical Investigation · 2019 · 297 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 297 citations

Medicine, Dermatology, Pharmacology +9